Meeting
2015 ASCO Annual Meeting
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
Authors
Eudocia Quant Lee
Dana-Farber Cancer Institute, Boston, MA
Eudocia Quant Lee , Alona Muzikansky , Elizabeth Robins Gerstner , John G. Kuhn , David A. Reardon , Lakshmi Nayak , Andrew David Norden , Lisa M. Doherty , Jennifer Rifenburg , Debra C. LaFrankie , Julee Pulverenti , Trupti Vardam-Kaur , Deirdre Stokes , Katrina Howard Smith , Christine Sceppa McCluskey , Sarah C. Gaffey , Tracy Batchelor , Dan G. Duda , Rakesh K. Jain , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01339039
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS2080)
DOI
10.1200/jco.2015.33.15_suppl.tps2080
Abstract #
TPS2080
Poster Bd #
68a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
First Author: Katrina H. Smith
Poster
2016 ASCO Annual Meeting
A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB).
First Author: Reena Parada Thomas
Poster
2015 ASCO Annual Meeting
A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01.
First Author: Jeffrey J. Raizer
Poster
2022 ASCO Annual Meeting
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.
First Author: David A. Reardon